Accent Microcell

Accent Microcell FCF/Debt

The Free Cash Flow to Debt Ratio of Accent Microcell (ACCENTMIC.NS) as of Oct 22, 2026 is 827.79 %. In the previous year, Free Cash Flow to Debt Ratio was 73.03 % — a change of 1,033.44% (higher).

FCF/Debt

827.79 %

YoY

1,033.44%

Last updated:

Free Cash Flow to Debt Ratio of Accent Microcell is 2025 827.79 % . Free Cash Flow to Debt Ratio of Accent Microcell was 2024 73.03 % . It decreases by 1,033.44% higher compared to the previous year.

The Accent Microcell FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2023
48.52 INR
Jan 1, 2024
73.03 INR
Jan 1, 2025
827.79 INR
The Accent Microcell FCF/Debt history
YEARFCF/DebtYoY
827.79 %+1,033.44%
73.03 %+50.52%
48.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accent Microcell Stock analysis

What does Accent Microcell do? Accent Microcell Ltd develops, processes, and markets a wide range of pharmaceutical products including bulk drugs, formulations in all forms, feed and dietary supplements, and healthcare products across allopathic, ayurvedic, umami, homeopathic, and other branches. The company manufactures and sells antibiotics, herbal, bacteriological, and biological products, as well as insecticides, pesticides, fungicides, and disinfectants. With over 200 products in its portfolio, Accent Microcell targets therapeutic segments in human and veterinary healthcare, offering both raw materials and finished preparations for diverse medical applications. The company's product range includes microcrystalline cellulose powder and alpha cellulose powder, which are used as pharmaceutical excipients. Accent Microcell Limited deals in all kinds of drugs and medicines, covering various therapeutic areas such as antibiotics, herbal remedies, and veterinary applications. Its business model focuses on manufacturing, importing, and exporting these products to meet demand in multiple healthcare sectors. Accent Microcell Ltd's revenue streams come from selling bulk drugs, pharmaceutical formulations, and healthcare products to distributors, pharmacies, and veterinary suppliers. The company's diverse portfolio of over 200 products ensures steady demand across different therapeutic segments, supporting consistent sales in both human and veterinary healthcare markets. Accent Microcell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accent Microcell stock

Free Cash Flow to Debt Ratio of Accent Microcell is 827.79 % in 2025.

Free Cash Flow to Debt Ratio of Accent Microcell changed from 73.03 % to 827.79 %, representing a 1,033.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Accent Microcell since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Accent Microcell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Accent Microcell

All Key Metrics — Accent Microcell